Long-Term Data Indicate Interferon Beta-1b Reduces the Risk of Death for Patients With MSAugust 1, 2012Multiple Sclerosis
Interferon Beta May Not Reduce Disability Progression for Patients With MSAugust 1, 2012Multiple Sclerosis
Should Patients Continue Natalizumab Treatment After a Positive JCV Test?August 1, 2012Multiple Sclerosis
Cognitive Rehabilitation Improves Quality of Life in Patients With MSAugust 1, 2012Multiple Sclerosis
Jeffrey A. Cohen, MD, Describes His Comparison of Alemtuzumab and Interferon Beta-1a in Patients With Multiple SclerosisJuly 1, 2012Multiple Sclerosis
Laquinimod May Be Effective for the Long-Term Management of Multiple SclerosisJuly 1, 2012Multiple Sclerosis
Data Are Unclear About the Effectiveness of Laquinimod in Multiple Sclerosis—by Stuart Cook, MDJuly 1, 2012Multiple Sclerosis
Tool Allows MS Patients to Assess How Their Impairment Compares to That of Other Patients With Same Disease DurationJuly 1, 2012Multiple Sclerosis
Combined Use of Interferon beta-1a and Glatiramer Acetate May Not Be Superior to Glatiramer Acetate Alone in Reducing MS RelapsesJuly 1, 2012Multiple Sclerosis
The CombiRx Trial Could Shed Light on the MS Disease Process—by Richard A. Rudick, MDJuly 1, 2012Multiple Sclerosis
Alemtuzumab Will Help Clinicians Treat Patients With MS More Effectively—By Mark Gudesblatt, MDJune 1, 2012Multiple Sclerosis
Alemtuzumab May Be Superior to Interferon Beta-1a in Patients With MS—Results From the CARE-MS II StudyJune 1, 2012Multiple Sclerosis
Alemtuzumab May Provide Greater Benefit Than Interferon Beta-1a for Treatment-Naïve Patients With MS—Results From the CARE-MS I StudyJune 1, 2012Multiple Sclerosis
